Licence Agreement with Cancer Research Technology

GB00B39J5N63

10 August 2010

                             Scancell Holdings Plc                             

                    (`Scancell Holdings' or the `Company')                     

          Antibody Licence Agreement with Cancer Research Technology           

Scancell Holdings Plc, (AIM:SCLP), the developer of therapeutic cancer
vaccines, and Cancer Research Technology Ltd (`CRT') - Cancer Research UK's
commercialisation and development arm - today announce that they have signed an
agreement under which Scancell has been granted a licence to use a human
antibody known as 105AD7.

105AD7 is a human monoclonal antibody that mimics the complement regulatory
protein, CD55. The antibody was discovered and originally developed at the
University of Nottingham with support from Cancer Research UK and has
previously been evaluated in clinical trials for osteosarcoma. The agreement
will give Scancell a worldwide licence to use 105AD7 for the development of new
ImmunoBody® vaccines for any immunotherapy indication.

The licence will be restricted to the use of the antibody as a framework for
future ImmunoBody® vaccines.

Scancell's current ImmunoBody® vaccines, such as SCIB1, its vaccine currently
in Phase I clinical trials for the treatment of melanoma, use a deimmunised*
antibody as the framework. 105AD7 will allow Scancell to use a fully human
framework for the development of future ImmunoBody® vaccines. 

Under the terms of the agreement, Scancell will make an upfront payment to CRT
in addition to development milestone payments, and royalty payments on future
sales. Scancell will exclusively fund the development work, and have
sub-licensing rights on agreed terms.

Professor Lindy Durrant, Chief Executive Officer of Scancell, commented:

"I am pleased that we have secured this important agreement with Cancer
Research Technology. By utilising antibody 105AD7, Scancell will be able to
further enhance the clinical utility and safety of Scancell's ImmunoBody®
platform both in cancer and other immunotherapy indications."

Dr Phil L'Huillier, Cancer Research Technology's director of business
management, said:

"Through this deal with Scancell we are able to take forward this antibody
arising from research from our world-class scientists into commercial
development to potentially make new vaccines to treat a range of diseases."

A copy of this announcement is available for download on the Company's website
at http://www.scancell.co.uk/

*Deimmunization is a technology for location and removal of T-cell epitopes
through the combined use of immunological and molecular biology techniques to
reduce the immunogenicity of an antibody.

                                    -ENDS-                                     

For further information contact:

Professor Lindy Durrant      Scancell Holdings Plc  + 44 (0)207 245 1100    
                                                                            
John Bick/Kirsty Corcoran    Hansard Communications + 44 (0)207 245 1100    
                                                                            
Ross Andrews/Tom Rowley      Zeus Capital           + 44 (0)161 831 1512    

About Scancell

Scancell is developing novel therapeutic vaccines for the treatment of cancer
and infectious diseases based on its groundbreaking ImmunoBody® technology
platform. Scancell's first cancer vaccine SCIB1 is being developed for the
treatment of melanoma and has recently entered clinical trials.

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be
administered to a patient, stimulating an immune response. Effective cancer
vaccines need to target dendritic cells to stimulate both parts of the cellular
immune system; the helper cell system where inflammation is stimulated at the
tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system
cells are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they
cannot specifically target dendritic cells in vivo. Several groups have
demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing
them with tumour antigens and re-infusing them. However, this procedure is
patient specific, time consuming and expensive. Scancell has developed its
breakthrough patent protected ImmunoBody® technology to overcome these
limitations.

An ImmunoBody® is a human antibody or fusion protein engineered to express
helper cell and CTL epitopes from tumour antigens over-expressed by cancer
cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour
antigens as they have long half-lives and can effectively target dendritic
cells via their Fc receptors, allowing efficient stimulation of both helper and
CTL responses.

The Immunobody® technology can be adapted to provide the basis for treating any
tumour type and may also be of potential utility in the development of vaccines
against hepatitis, HIV and other chronic infectious diseases.

About Cancer Research Technology Ltd

Cancer Research Technology Limited (CRT) is a specialist commercialisation and
development company, which aims to develop new discoveries in cancer research
for the benefit of cancer patients. CRT works closely with leading
international cancer scientists and their institutes to protect intellectual
property arising from their research and to establish links with commercial
partners. CRT facilitates the discovery, development and marketing of new
cancer therapeutics, vaccines, diagnostics and enabling technologies. CRT is
wholly owned by Cancer Research UK, the largest independent funder of cancer
research in the world.

CRT's discovery laboratories build on exploratory research to create attractive
commercial opportunities through collaboration with research institutes
worldwide. Therapeutic programmes are then out-licensed for further development
following identification of a suitable partner.

For more information visit the web site www.cancertechnology.com

About Cancer Research UK

  * Cancer Research UK is the world's leading charity dedicated to beating
    cancer through research.
   
  * The charity's groundbreaking work into the prevention, diagnosis and
    treatment of cancer has helped save millions of lives.  This work is funded
    entirely by the public.
   
  * Cancer Research UK has been at the heart of the progress that has already
    seen survival rates double in the last forty years.
   
  * Cancer Research UK supports research into all aspects of cancer through the
    work of more than 4,800 scientists, doctors and nurses.
   
  * Together with its partners and supporters, Cancer Research UK's vision is
    to beat cancer.
   
  * For further information about Cancer Research UK's work or to find out how
    to support the charity, please call 020 7121 6699 or visit 
    www.cancerresearchuk.org.uk.